Novexel has begun Phase II trials on a advanced oral antibacterial NXL103 designed to treat adults with acute bacterial skin and skin structure infections.

The multicentre, investigator-blinded, two-arm, parallel group study will assess the safety and efficacy of NXL103 in comparison to oral linezolid.

The study is expected to be completed in 2010 and is a critical part of Novexel’s development plan for NXL103 which will be used in hospitals and out-patients as an oral agent for the treatment of infections caused by gram-positive organisms, including MRSA.

Novexel CEO Iain Buchanan said that there was a clear need for products that can be used to manage the release of patients from hospital by allowing them to be switched from intravenous to oral therapy.

“Currently, physicians have a limited choice of anti-MRSA antibacterials when they wish to switch from intravenous (IV) to oral treatment, a key step prior to a patient being able to be discharged from the hospital,” he said.

NXL103 is as a member of the Streptogramin class of antibiotics, which has a unique mode of action, with its two components acting synergistically to inhibit the bacterial ribosome.